Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
IPO Year:
Exchange: NASDAQ
Website: ocuphire.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/24/2021 | $26.00 | Buy | HC Wainwright & Co. |
Submission status for OCUPHIRE PHARMA INC's drug RYZUMVI (ORIG-1) with active ingredient PHENTOLAMINE has changed to 'Approval' on 09/25/2023. Application Category: NDA, Application Number: 217064, Application Classification: Type 3 - New Dosage Form
HC Wainwright & Co. initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $26.00
Alliance Global Partners initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $25.00
JonesTrading initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald reiterated coverage of Ocuphire Pharma with a rating of Overweight and set a new price target of $20.00 from $15.00 previously
Cantor Fitzgerald reiterated coverage of Ocuphire Pharma with a rating of Positive and set a new price target of $20.00 from $15.00 previously
Canaccord Genuity initiated coverage of Ocuphire Pharma with a rating of Buy and set a new price target of $22.00
Canaccord Genuity initiated coverage of Ocuphire Pharma with a rating of Buy